

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q94143

Ikuo MORITA, et al.

Appln. No.: 10/574,687

Group Art Unit: 1636

Confirmation No.: 3712

Examiner: Taeyoon KIM

Filed: April 5, 2006

For: METHOD OF CONSTRUCTING ARTIFICIAL CELL TISSUE AND BASE MATERIAL
THEREOF

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1 JP 03-198771 A published 1991-08-29 to Sanyo Electric Co., Ltd. with English Abstract.

2 WO 98/51785 A1 published 1998-11-19 to The General Hospital Corp.

3 JP 02-211865 A published 1990-08-23 to Kao Corp. and Tokyo Jiyoshi Ika with English Abstract.

4 JP 04-004869 A published 1992-01-09 to Toray Ind. Inc. with English Abstract.

5 JP 04-094679 A published 1992-03-26 to Kao Corp. and Tokyo Jiyoshi Ika with English Abstract.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98
U.S. Appln. No.: 10/574,687

Attorney Docket No.: Q94143

6 JP 04-126071 A published 1992-04-27 to Kao Corp. and Tokyo Jiyoshi Ika with English Abstract.

One copy of each of the listed documents is submitted herewith along with a copy of a Communication from a foreign patent office in a counterpart application citing such documents. It is noted that the remaining references identified on the Japanese Office Action dated April 1, 2008 were previously submitted with Information Disclosure Statements. JP 2002-355031, 2003-228172, and 2003-22262 were previously submitted to the USPTO on December 26, 2007 and EP 1 246 011 was previously submitted to the USPTO on April 5, 2006.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant relies on the English Abstracts as brief statements of relevance.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98
U.S. Appln. No.: 10/574,687

Attorney Docket No.: Q94143

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 12, 2008



John T. Callahan
Registration No. 32,607